1. Home
  2. OCFC vs TYRA Comparison

OCFC vs TYRA Comparison

Compare OCFC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OceanFirst Financial Corp.

OCFC

OceanFirst Financial Corp.

HOLD

Current Price

$18.56

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$32.86

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCFC
TYRA
Founded
1902
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
OCFC
TYRA
Price
$18.56
$32.86
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$21.33
$44.63
AVG Volume (30 Days)
571.7K
740.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.43%
N/A
EPS Growth
N/A
6.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$46.71
N/A
Revenue Next Year
$21.25
N/A
P/E Ratio
$16.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.29
$6.42
52 Week High
$20.61
$35.71

Technical Indicators

Market Signals
Indicator
OCFC
TYRA
Relative Strength Index (RSI) 44.96 57.45
Support Level $17.24 $26.14
Resistance Level $19.11 N/A
Average True Range (ATR) 0.61 2.63
MACD -0.13 0.13
Stochastic Oscillator 40.68 71.05

Price Performance

Historical Comparison
OCFC
TYRA

About OCFC OceanFirst Financial Corp.

OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: